<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS188714</article-id><article-id pub-id-type="doi">10.1101/2023.09.26.559634</article-id><article-id pub-id-type="archive">PPR731717</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Expansion of interferon signaling-associated gene (ISAG)<sup>hi</sup> T cells in early-onset Alzheimer’s disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sirkis</surname><given-names>Daniel W.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Solsberg</surname><given-names>Caroline Warly</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Taylor P.</given-names></name><degrees>BA</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Geier</surname><given-names>Ethan G.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bonham</surname><given-names>Luke W.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Bruce L.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Rabinovici</surname><given-names>Gil D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yokoyama</surname><given-names>Jennifer S.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="corresp" rid="CR1">‡</xref></contrib></contrib-group><aff id="A1"><label>1</label>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA</aff><aff id="A2"><label>2</label>Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA</aff><aff id="A3"><label>3</label>Transposon Therapeutics, Inc., San Diego, CA 92122, USA</aff><aff id="A4"><label>4</label>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94158, USA</aff><aff id="A5"><label>5</label>Global Brain Health Institute, University of California, San Francisco, San Francisco, CA 94158, USA and Trinity College Dublin, Dublin, Ireland</aff><author-notes><corresp id="CR1">
<label>‡</label>Correspondence: <email>jennifer.yokoyama@ucsf.edu</email>, Weill Institute for Neurosciences, 1651 4<sup>th</sup> Street, San Francisco, CA 94158, (415) 476-5565</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>29</day><month>09</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>27</day><month>09</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Importance</title><p id="P1">Altered immune signatures are emerging as a central theme in neurodegenerative disease, yet little is known about immune responses in early-onset Alzheimer’s disease (EOAD).</p></sec><sec id="S2"><title>Objective</title><p id="P2">To determine whether an EOAD-specific immune signal can be detected in blood.</p></sec><sec id="S3"><title>Design</title><p id="P3">We examined single-cell RNA-sequencing (scRNA-seq) data from peripheral blood mononuclear cells (PBMCs) and droplet digital (dd)PCR data from CD4 T cells from participants with EOAD and clinically normal controls.</p></sec><sec id="S4"><title>Setting</title><p id="P4">University of California, San Francisco Memory and Aging Center.</p></sec><sec id="S5"><title>Participants</title><p id="P5">Samples were collected for the study from 2017 to 2021. Participants with EOAD were diagnosed with AD prior to age 65. Data were last analyzed September 2023.</p></sec><sec id="S6"><title>Main Outcomes and Measures</title><p id="P6">The primary analysis (scRNA-seq) examined whether EOAD was associated with altered frequency of any PBMC subsets. Secondary analysis (ddPCR) measured marker gene expression in CD4 T cells.</p></sec><sec id="S7"><title>Results</title><p id="P7">Over 182,000 individual PBMC transcriptomes were analyzed by scRNA-seq from 16 individuals (mean [SD] age at sample collection, 52.2 [9.6] years; 8 [50.0%] were female; 8 [50.0%] had clinical diagnosis of AD). The relative abundance of PBMC subsets was tested for association with EOAD while controlling for age and sex. Of 19 PBMC clusters, one cluster, representing interferon signaling-associated gene (ISAG)<sup>hi</sup> T cells, was significantly expanded in EOAD (<italic>P</italic> = 0.005). A validation cohort consisting of 19 individuals (mean [SD] age at sample collection, 57.7 [4.1] years; 13 [68.4%] were female; 9 [47.4%] had clinical diagnosis of AD) was used for CD4 T cell isolation and ddPCR analysis. Expression of <italic>MX1</italic> and <italic>IFI6</italic>, marker genes for ISAG<sup>hi</sup> T cells, was significantly elevated in participants with EOAD (<italic>P</italic> = 0.002 and <italic>P</italic> = 0.04, respectively). Secondary analyses of independent scRNA-seq datasets from later-onset AD and familial tauopathy indicated that ISAG<sup>hi</sup> T cells are detected but not elevated in these related diseases.</p></sec><sec id="S8"><title>Conclusions and Relevance</title><p id="P8">ISAG<sup>hi</sup> T cells, which appear primed for antiviral activity, are significantly and specifically expanded in EOAD. Additional research into the role of this rare cell type in neurodegeneration is warranted.</p></sec></abstract></article-meta></front><body><sec id="S9" sec-type="intro"><title>Introduction</title><p id="P9">Approximately 5–10% of the ~7 million Americans living with Alzheimer’s disease (AD)<sup><xref ref-type="bibr" rid="R1">1</xref></sup> experience symptom onset prior to age 65<sup><xref ref-type="bibr" rid="R2">2</xref></sup>. In this early-onset form of AD (EOAD), affected individuals are more likely to experience an aggressive clinical course, have an atypical clinical syndrome, encounter delays in diagnosis, and experience unique social disruptions due to their relatively young age<sup><xref ref-type="bibr" rid="R2">2</xref></sup>. The vast majority (≥90%) of EOAD cases are not inherited in an autosomal-dominant manner, and for these individuals, we understand relatively little about the genetic and other biological factors underpinning disease risk.</p><p id="P10">Recent reports using single-cell RNA-sequencing (scRNA-seq) have highlighted changes in peripheral blood and cerebrospinal fluid (CSF) leukocyte populations in AD<sup><xref ref-type="bibr" rid="R3">3</xref></sup>, Lewy body dementia<sup><xref ref-type="bibr" rid="R4">4</xref></sup>, familial tauopathy<sup><xref ref-type="bibr" rid="R5">5</xref></sup>, and during aging<sup><xref ref-type="bibr" rid="R6">6</xref></sup>. To our knowledge, however, a global, unbiased scRNA-seq analysis of peripheral blood mononuclear cells (PBMCs) in EOAD has not been reported. Using scRNA-seq, we now find evidence for marked expansion of a small population of recently characterized CD4 T cells expressing very high levels of interferon (IFN) signaling-associated genes (ISAG<sup>hi</sup> T cells) in EOAD. We also observe global up-regulation of ISAG<sup>hi</sup> T-cell marker genes across additional lymphoid and myeloid PBMC types. Strikingly, although we also detect ISAG<sup>hi</sup> T cells in a well-known dataset of CSF leukocytes derived primarily from individuals with older-onset AD and mild cognitive impairment (MCI)<sup><xref ref-type="bibr" rid="R3">3</xref></sup>, the cluster is not expanded in these cases, suggesting ISAG<sup>hi</sup> T cells may be specific to EOAD. In addition, a CD4 T-cell subtype that appears to be highly similar to ISAG<sup>hi</sup> T cells–with a similar antiviral gene expression signature–is markedly expanded in the CSF in the context of viral encephalitis<sup><xref ref-type="bibr" rid="R7">7</xref></sup>, suggesting that EOAD-expanded ISAG<sup>hi</sup> T cells have antiviral properties.</p></sec><sec id="S10" sec-type="methods"><title>Methods</title><p id="P11">After obtaining informed consent, PBMCs from study participants (<xref ref-type="table" rid="T1">Table 1</xref>) at the University of California, San Francisco Memory and Aging Center were analyzed by scRNA-seq essentially as described<sup><xref ref-type="bibr" rid="R5">5</xref></sup>. Details are described in <xref ref-type="supplementary-material" rid="SD7">eMethods</xref>. Raw sequencing reads were aligned to GRCh38-2020-A and feature-barcode matrices generated using Cell Ranger (v7.1.0) with intronic reads excluded. Cluster proportions were determined for individual samples by dividing the number of cells in a given cluster by the total number of cells in clusters representing all PBMCs, all T cells, or all CD4 T cells (after quality control) for each individual. Statistical differences in cell-type abundances by diagnosis were assessed via linear modeling, controlling for age and sex.</p></sec><sec id="S11" sec-type="results"><title>Results</title><p id="P12">After QC filtering, clustering of ~182,000 PBMCs generated 19 primary clusters consisting of all expected PBMC types. Comparison of relative cluster abundance in EOAD cases vs. controls revealed a single cluster (cluster 15) that was robustly expanded in EOAD (<xref ref-type="fig" rid="F1">Figure 1, A</xref>). Expression of marker genes indicates that cluster 15 is a subtype of CD4 T cell (<xref ref-type="supplementary-material" rid="SD1">eFigure 1, A</xref>). Quantification of cluster 15 abundance relative to either all PBMCs, all T cells, or all CD4 T cells revealed significant expansion in EOAD that is driven primarily by females (<xref ref-type="fig" rid="F1">Figure 1, B, C</xref>). To determine what type of CD4 T cell cluster 15 represents, we subsetted all T cells and reclustered them separately from all other cell types. Reclustering revealed this cell type in sub-cluster 11, which expresses uniquely high levels of IFN-signaling genes <italic>MX1</italic> and <italic>IFI6</italic> relative to all other T cells (<xref ref-type="fig" rid="F1">Figure 1, D</xref>). As expected, sub-cluster 11 was also significantly expanded in EOAD relative to controls (<xref ref-type="fig" rid="F1">FIgure 1, D</xref>).</p><p id="P13">What is the precise identity of this subset of CD4 T cells? Recent literature using scRNA-seq to analyze human leukocyte populations has revealed two poorly understood cell types: ISAG<sup>hi</sup> T cells, detected in peripheral blood<sup><xref ref-type="bibr" rid="R8">8</xref></sup>, and antiviral CD4 T cells, detected in CSF<sup><xref ref-type="bibr" rid="R7">7</xref></sup>. Antiviral CD4 T cells were so named due to their marker gene expression and robust expansion in the CSF in the context of viral encephalitis<sup><xref ref-type="bibr" rid="R7">7</xref></sup>. Comparison of all marker genes for our sub-cluster 11 to the top 200 marker genes for CSF antiviral CD4 T cells revealed highly statistically significant overlap <italic>(P</italic> = 6.5 x 10<sup>-14</sup>; <xref ref-type="supplementary-material" rid="SD2">eTable 1</xref>)<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. Moreover, all of the 12 most-significant marker genes originally reported for ISAG<sup>hi</sup> T cells<sup><xref ref-type="bibr" rid="R8">8</xref></sup> are also top marker genes of our sub-cluster 11 and of antiviral CD4 T cells. Therefore, from here on we refer to the EOAD-expanded CD4 T cells as ISAG<sup>hi</sup> T cells.</p><p id="P14">ISAG<sup>hi</sup> T-cell abundance was consistent across scRNA-seq batches (<xref ref-type="supplementary-material" rid="SD1">eFigure 1, B</xref>) and was not driven by <italic>APOE</italic> ε4 status (<xref ref-type="supplementary-material" rid="SD1">eFigure 1, C</xref>). Moreover, although our control samples came from participants with a younger mean age (<xref ref-type="table" rid="T1">Table 1</xref>), there was no relationship between age and ISAG<sup>hi</sup> abundance (<xref ref-type="supplementary-material" rid="SD1">eFigure 1, D</xref>). To increase the sample size of our scRNA-seq dataset, we included 7 additional control PBMC samples previously characterized by scRNA-seq<sup><xref ref-type="bibr" rid="R5">5</xref></sup>. We found that the expansion of ISAG<sup>hi</sup> T cells relative to PBMCs and all T cells remained significant after addition of these independent controls, although one outlier control sample with very high levels of ISAG<sup>hi</sup> T cells made the findings somewhat less robust (<xref ref-type="supplementary-material" rid="SD1">eFigure 2</xref>). We recently reported a reduction in peripheral non-classical monocytes in familial tauopathy<sup><xref ref-type="bibr" rid="R5">5</xref></sup>. Comparing the familial tauopathy and EOAD datasets, we found that non-classical monocytes are not reduced in EOAD, and ISAG<sup>hi</sup> T cells are not expanded in familial tauopathy (<xref ref-type="supplementary-material" rid="SD1">eFigure 3</xref>). Moreover, secondary analysis of a well-known CSF leukocyte dataset<sup><xref ref-type="bibr" rid="R3">3</xref></sup> revealed that ISAG<sup>hi</sup> T cells, although detected, are also not expanded in the CSF in an independent cohort consisting of mostly later-onset MCI and AD cases (<xref ref-type="supplementary-material" rid="SD1">eFigure 4</xref>). Collectively, these findings suggest that ISAG<sup>hi</sup> T-cell expansion may be associated specifically with EOAD rather than LOAD or familial tauopathy.</p><p id="P15">Differential expression analysis revealed a high number of differentially expressed genes (DEGs) in classical and non-classical monocytes in EOAD, relative to cognitively normal controls (<xref ref-type="supplementary-material" rid="SD1">eFigure 5</xref>, <xref ref-type="supplementary-material" rid="SD3">eTable 2</xref>). Remarkably, we found that, on average, ~18% of the significantly up-regulated genes across all clusters (excluding those with fewer than 10 up-regulated DEGs) were also ISAG<sup>hi</sup> T-cell marker genes (<xref ref-type="supplementary-material" rid="SD1">eFigure 5</xref>). In EOAD, we thus observe both expansion of a CD4 T-cell subset expressing very high levels of genes associated with IFN signaling and up-regulation of many of the same genes across additional lymphoid and myeloid cell types.</p><p id="P16">To validate our primary scRNA-seq finding, we magnetically isolated CD4 T cells from an additional cohort of EOAD cases and control participants. A droplet digital (dd)PCR-based validation assay indicated highly efficient isolation of CD4 T cells (<xref ref-type="supplementary-material" rid="SD1">eFigure 6</xref>). Reasoning that increased expression of specific ISAG<sup>hi</sup> marker genes from isolated CD4 T cells would be consistent with expansion of ISAG<sup>hi</sup> T cells as well as ISAG up-regulation, we performed ddPCR for ISAG<sup>hi</sup> T-cell marker genes <italic>MX1</italic> and <italic>IFI6</italic> (<xref ref-type="fig" rid="F2">Figure 2, A</xref>). Cases and controls in the ddPCR cohort had similar average ages (<xref ref-type="table" rid="T1">Table 1</xref>; see also <xref ref-type="supplementary-material" rid="SD7">eMethods</xref>), excluding age as an explanatory factor for this finding. Strikingly, ddPCR confirmed increased <italic>MX1</italic> and <italic>IFI6</italic> signals in CD4 T cells from EOAD (<xref ref-type="fig" rid="F2">Figure 2, B</xref>). Increased <italic>MX1</italic> was observed across two independent ddPCR batches and was driven by females (<xref ref-type="fig" rid="F2">Figure 2, C</xref>).</p></sec><sec id="S12" sec-type="discussion"><title>Discussion</title><p id="P17">In this study, we found evidence for a unique peripheral immune signature in EOAD. Our findings complement and expand upon existing evidence of diverse T-cell signatures in other forms of AD<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R10">10</xref></sup>, additional neurodegenerative diseases<sup><xref ref-type="bibr" rid="R4">4</xref></sup>, and during aging<sup><xref ref-type="bibr" rid="R6">6</xref></sup>. Our study is limited by the relatively small sample sizes that are characteristic of scRNA-seq experiments. Future studies in diverse EOAD cohorts from additional recruitment sites will be needed to confirm the broad relevance of our findings to EOAD. In light of recent findings suggesting that (i) herpes zoster vaccination may be causally associated with reduced dementia risk in women<sup><xref ref-type="bibr" rid="R11">11</xref></sup>; (ii) viral encephalitis exposure markedly increases risk for AD<sup><xref ref-type="bibr" rid="R12">12</xref></sup>; and (iii) the ISAG<sup>hi</sup> T cells increased in EOAD bear striking resemblance to antiviral CD4 T cells expanded in CSF in viral encephalitis<sup><xref ref-type="bibr" rid="R7">7</xref></sup>, our findings raise the intriguing possibility that this extreme form of AD is characterized by a potent antiviral T-cell response.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>eFigures</label><media xlink:href="EMS188714-supplement-eFigures.pdf" mimetype="application" mime-subtype="pdf" id="d23aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>eTable 1</label><media xlink:href="EMS188714-supplement-eTable_1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d23aAdEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>eTable 2</label><media xlink:href="EMS188714-supplement-eTable_2.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d23aAdEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>eTable 3</label><media xlink:href="EMS188714-supplement-eTable_3.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d23aAdEeB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><label>eTable 4</label><media xlink:href="EMS188714-supplement-eTable_4.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d23aAdEfB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD6"><label>eTable 5</label><media xlink:href="EMS188714-supplement-eTable_5.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d23aAdEgB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD7"><label>Supplemental Online Content</label><media xlink:href="EMS188714-supplement-Supplemental_Online_Content.pdf" mimetype="application" mime-subtype="pdf" id="d23aAdEhB" position="anchor"/></supplementary-material></sec></body><back><ack id="S13"><title>Acknowledgments</title><p>J.S.Y. receives funding from NIH-NIA R01AG062588, R01AG057234, P30AG062422, P01AG019724, and U19AG079774; NIH-NINDS U54NS123985; NIH-NIDA 75N95022C00031; the Rainwater Charitable Foundation; the Bluefield Project to Cure Frontotemporal Dementia; the Alzheimer’s Association; the Global Brain Health Institute; the French Foundation; and the Mary Oakley Foundation. J.S.Y. serves on the scientific advisory board for the Epstein Family Alzheimer’s Research Collaboration. G.D.R. receives research funding from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, and Genentech. He has received consulting fees from Alector, Eli Lilly, Genentech, Roche, Merck. He receives fees for serving on a DSMB for Johnson &amp; Johnson. He is an Associate Editor for JAMA Neurology. B.L.M. reports grants from the NIA during the study; serves as medical advisor for the French Foundation; serves as scientific advisor for the Larry L. Hillblom Foundation, the Association for Frontotemporal Degeneration, the NIHR Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia, and the Buck Institute for Research on Aging; serves as external advisor for the University of Washington ADRC, Stanford University ADRC, Arizona Alzheimer’s Disease Center, and Massachusetts ADRC; and serves on the external advisory committee for the University of Southern California P01 Urban Air Pollution and Alzheimer’s Disease: Risk, Heterogeneity and Mechanisms. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The cartoon in <xref ref-type="fig" rid="F2">Figure 2</xref> was created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>.</p></ack><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><article-title>2023 Alzheimer’s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2023</year><volume>19</volume><issue>4</issue><fpage>1598</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">36918389</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirkis</surname><given-names>DW</given-names></name><name><surname>Bonham</surname><given-names>LW</given-names></name><name><surname>Johnson</surname><given-names>TP</given-names></name><name><surname>La Joie</surname><given-names>R</given-names></name><name><surname>Yokoyama</surname><given-names>JS</given-names></name></person-group><article-title>Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease</article-title><source>Mol Psychiatry</source><year>2022</year><volume>27</volume><issue>6</issue><fpage>2674</fpage><lpage>2688</lpage><pub-id pub-id-type="pmcid">PMC9156414</pub-id><pub-id pub-id-type="pmid">35393555</pub-id><pub-id pub-id-type="doi">10.1038/s41380-022-01531-9</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gate</surname><given-names>D</given-names></name><name><surname>Saligrama</surname><given-names>N</given-names></name><name><surname>Leventhal</surname><given-names>O</given-names></name><etal/></person-group><article-title>Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease</article-title><source>Nature</source><year>2020</year><volume>577</volume><issue>7790</issue><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmcid">PMC7445078</pub-id><pub-id pub-id-type="pmid">31915375</pub-id><pub-id pub-id-type="doi">10.1038/s41586-019-1895-7</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gate</surname><given-names>D</given-names></name><name><surname>Tapp</surname><given-names>E</given-names></name><name><surname>Leventhal</surname><given-names>O</given-names></name><etal/></person-group><article-title>CD4 T cells contribute to neurodegeneration in Lewy body dementia</article-title><source>Science</source><year>2021</year><volume>374</volume><issue>6569</issue><fpage>868</fpage><lpage>874</lpage><pub-id pub-id-type="pmcid">PMC9122025</pub-id><pub-id pub-id-type="pmid">34648304</pub-id><pub-id pub-id-type="doi">10.1126/science.abf7266</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirkis</surname><given-names>DW</given-names></name><name><surname>Warly Solsberg</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Single-cell RNA-seq reveals alterations in peripheral CX3CR1 and nonclassical monocytes in familial tauopathy</article-title><source>Genome Med</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="pmcid">PMC10354988</pub-id><pub-id pub-id-type="pmid">37464408</pub-id><pub-id pub-id-type="doi">10.1186/s13073-023-01205-3</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piehl</surname><given-names>N</given-names></name><name><surname>van Olst</surname><given-names>L</given-names></name><name><surname>Ramakrishnan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment</article-title><source>Cell</source><year>2022</year><volume>185</volume><issue>26</issue><fpage>5028</fpage><lpage>5039</lpage><elocation-id>e13</elocation-id><pub-id pub-id-type="pmcid">PMC9815831</pub-id><pub-id pub-id-type="pmid">36516855</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2022.11.019</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heming</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Räuber</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid</article-title><source>Immunity</source><year>2021</year><volume>54</volume><issue>1</issue><fpage>164</fpage><lpage>175</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmcid">PMC7831653</pub-id><pub-id pub-id-type="pmid">33382973</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2020.12.011</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Reinvestigation of Classic T Cell Subsets and Identification of Novel Cell Subpopulations by Single-Cell RNA Sequencing</article-title><source>J Immunol</source><year>2022</year><volume>208</volume><issue>2</issue><fpage>396</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">34911770</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amand</surname><given-names>J</given-names></name><name><surname>Fehlmann</surname><given-names>T</given-names></name><name><surname>Backes</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name></person-group><article-title>DynaVenn: web-based computation of the most significant overlap between ordered sets</article-title><source>BMC Bioinformatics</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>743</fpage><pub-id pub-id-type="pmcid">PMC6937821</pub-id><pub-id pub-id-type="pmid">31888436</pub-id><pub-id pub-id-type="doi">10.1186/s12859-019-3320-5</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><article-title>Spontaneous and induced adaptive immune responses in Alzheimer’s disease: new insights into old observations</article-title><source>Curr Opin Immunol</source><year>2022</year><volume>77</volume><elocation-id>102233</elocation-id><pub-id pub-id-type="pmid">35839620</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyting</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Heß</surname><given-names>S</given-names></name><name><surname>Heß</surname><given-names>S</given-names></name><name><surname>Geldsetzer</surname><given-names>P</given-names></name></person-group><article-title>Causal evidence that herpes zoster vaccination prevents a proportion of dementia cases</article-title><source>medRxiv</source><comment>Published online May 25, 2023</comment><pub-id pub-id-type="doi">10.1101/2023.05.23.23290253</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>KS</given-names></name><name><surname>Leonard</surname><given-names>HL</given-names></name><name><surname>Blauwendraat</surname><given-names>C</given-names></name><etal/></person-group><article-title>Virus exposure and neurodegenerative disease risk across national biobanks</article-title><source>Neuron</source><year>2023</year><volume>111</volume><issue>7</issue><fpage>1086</fpage><lpage>1093</lpage><elocation-id>e2</elocation-id><pub-id pub-id-type="pmcid">PMC10079561</pub-id><pub-id pub-id-type="pmid">36669485</pub-id><pub-id pub-id-type="doi">10.1016/j.neuron.2022.12.029</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Key Points</title></caption><sec id="S14"><title>Question</title><p>Is early-onset Alzheimer’s disease (EOAD) associated with a specific peripheral immune signature?</p></sec><sec id="S15"><title>Findings</title><p>We performed single-cell RNA-sequencing of &gt;182,000 peripheral blood mononuclear cells and identified striking expansion of a subset of CD4 T cells termed interferon (IFN) signaling-associated gene (ISAG)<sup>hi</sup> T cells. We confirmed this finding by isolating CD4 T cells from additional participants with EOAD and measuring increased expression of ISAG<sup>hi</sup> marker genes.</p></sec><sec id="S16"><title>Meaning</title><p>ISAG<sup>hi</sup> cells, which are primed for antiviral response, are expanded in early- but not late-onset AD or primary familial tauopathy, suggesting they may provide unique insight into the immune response to EOAD.</p></sec></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>Expansion of ISAG<sup>hi</sup> T cells in EOAD characterized by scRNA-seq.</title><p><bold>A</bold>, Uniform manifold approximation and projection (UMAP) plot of ~182,000 PBMCs from EOAD cases and cognitively normal controls, colored by cluster identity. Major cell types are labeled within the plot. The inset (right) shows the primary T-cell grouping displayed in grey, with the ISAG<sup>hi</sup> T-cell cluster shown in magenta. <bold>B</bold>, ISAG<sup>hi</sup> T-cell abundance is quantified relative to all PBMCs (left; <italic>P</italic> = 0.005), all T cells (middle, <italic>P</italic> = 0.013), and all CD4 T cells (right; <italic>P</italic> = 0.016). <bold>C</bold>, Stratifying by sex, ISAG<sup>hi</sup> T-cell relative abundance is significantly increased in EOAD only in females, expressed as a percentage of PBMCs (left, <italic>P</italic> = 0.006), T cells (middle, <italic>P</italic> = 0.01), and CD4 T cells (right, <italic>P</italic> = 0.008). <bold>D</bold>, Reclustering of all T cells (left) generates a T-cell subcluster (11) representing ISAG<sup>hi</sup> T cells, which express high levels of marker genes <italic>MX1</italic> and <italic>IFI6</italic>, in addition to T-cell markers <italic>CD4</italic> and <italic>CD3E</italic> (middle). Quantification of the ISAG<sup>hi</sup> subcluster relative to all T cells again indicates a significant increase in EOAD cases (right, <italic>P</italic> = 0.034).</p></caption><graphic xlink:href="EMS188714-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>ISAG<sup>hi</sup> T-cell marker gene expression is increased in CD4 T cells in EOAD.</title><p><bold>A</bold>, CD4 T cells were magnetically isolated from PBMCs and RNA was extracted; gene expression was determined by RT-ddPCR. <bold>B</bold>, Expression of <italic>MX1</italic> and <italic>IFI6</italic> was significantly increased in CD4 T cells from EOAD cases relative to cognitively normal controls (<italic>P</italic> = 0.002 and <italic>P</italic> = 0.04, respectively). <bold>C</bold>, <italic>MX1</italic> expression was significantly increased in two independent RT-ddPCR batches (<italic>P</italic> = 0.03, both batches). The increase in <italic>MX1</italic> expression observed in EOAD was driven by females (<italic>P</italic> = 0.0002). <italic>CD4</italic> was used as a reference gene.</p></caption><graphic xlink:href="EMS188714-f002"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Demographic and experimental information for samples used in scRNA-seq and ddPCR studies</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" rowspan="2"/><th align="center" valign="top" colspan="2">scRNA-seq discovery study</th><th align="center" valign="top" colspan="2">ddPCR validation study</th></tr><tr><th align="center" valign="top">Controls</th><th align="center" valign="top">Cases</th><th align="center" valign="top">Controls</th><th align="center" valign="top">Cases</th></tr></thead><tbody><tr><td align="center" valign="top"><italic>n</italic></td><td align="center" valign="top">8</td><td align="center" valign="top">8</td><td align="center" valign="top">10</td><td align="center" valign="top">9</td></tr><tr><td align="center" valign="top"><italic>n</italic> per batch (Batch A, Batch B)</td><td align="center" valign="top">4, 4</td><td align="center" valign="top">4, 4</td><td align="center" valign="top">5, 5</td><td align="center" valign="top">4, 5</td></tr><tr><td align="center" valign="top">PBMCs analyzed, <italic>n</italic></td><td align="center" valign="top">91,955</td><td align="center" valign="top">90,398</td><td align="center" valign="top">N/A</td><td align="center" valign="top">N/A</td></tr><tr><td align="center" valign="top">CD4 T-cell RIN, mean (SD)</td><td align="center" valign="top">N/A</td><td align="center" valign="top">N/A</td><td align="center" valign="top">9.5 (0.5)</td><td align="center" valign="top">9.5 (0.3)</td></tr><tr><td align="center" valign="top">Sex, <italic>n</italic> female (%)</td><td align="center" valign="top">4 (50)</td><td align="center" valign="top">4 (50)</td><td align="center" valign="top">7 (70)</td><td align="center" valign="top">6 (66.7)</td></tr><tr><td align="center" valign="top">Age, mean (SD)</td><td align="center" valign="top">44.6 (7.4)</td><td align="center" valign="top">59.9 (3.1)</td><td align="center" valign="top">56.9 (5.0)</td><td align="center" valign="top">58.6 (2.7)</td></tr><tr><td align="center" valign="top"><italic>APOE</italic> ε4 status <italic>n</italic> heterozygous, <italic>n</italic> homozygous</td><td align="center" valign="top">3, 0</td><td align="center" valign="top">5, 1</td><td align="center" valign="top">2, 0</td><td align="center" valign="top">5, 1</td></tr><tr><td align="center" valign="top">Clinical syndrome (<italic>n</italic>)</td><td align="center" valign="top">clinically normal (8)</td><td align="center" valign="top">AD (6), frontal AD (2)</td><td align="center" valign="top">clinically normal (10)</td><td align="center" valign="top">AD (9)</td></tr><tr><td align="center" valign="top">Global CDR, mean (SD)</td><td align="center" valign="top">0.0 (0.0)</td><td align="center" valign="top">1.1 (0.4)</td><td align="center" valign="top">0.1 (0.2)<xref ref-type="table-fn" rid="TFN2">#</xref></td><td align="center" valign="top">0.9 (0.2)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P18">Abbreviations: AD, Alzheimer’s disease; CDR, Clinical Dementia Rating scale; ddPCR, droplet digital PCR; PBMC, peripheral blood mononuclear cell; scRNA-seq, single-cell RNA sequencing; RIN, RNA integrity number; SD, standard deviation.</p></fn><fn id="TFN2"><label>#</label><p id="P19">All clinically normal control participants except one in the ddPCR study had a Global CDR score of 0; the remaining control had a global CDR score of 0.5 and was considered clinically normal by neurological and neuropsychological testing.</p></fn></table-wrap-foot></table-wrap></floats-group></article>